Patient-Centered Outcomes in the Surgical Treatment of Uterovaginal Prolapse

NCT ID: NCT05063331

Last Updated: 2025-12-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

320 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-12-15

Study Completion Date

2030-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare two types of surgery for the treatment of uterovaginal prolapse to determine which surgery works best from a patient's perspective and has the lowest number of short-term and long-term complications.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multi-site, randomized controlled trial, where women with the confirmed diagnosis of uterovaginal prolapse will be randomized in a 1:1 ratio to either A) a minimally invasive supracervical hysterectomy with sacrocolpopexy (MI-SCH+SCP) or B) total vaginal hysterectomy with uterosacral ligament suspension (TVH+USLS). After surgery, participants will be followed for 3 years including physical pelvic exams and validated symptom questionnaires to assess for the primary and secondary outcomes. A subset of participants will participate in semi-structured interviews, before surgery and through 2 years after surgery, that will assess patient recovery, satisfaction with care, and calibrate surveyed and clinically assessed outcomes to the daily life experiences of women.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Uterine Prolapse

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

The study is utilizing a 1:1 randomization scheme (by site) to assign patients to one of two treatment arms: 1) minimally invasive supracervical hysterectomy with sacrocolpopexy (MI-SCH+SCP, N=160) or 2) total vaginal hysterectomy with uterosacral ligament suspension (TVH+USLS, N=160).
Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants
Participants will be masked to the surgical randomization prior to surgery and will be informed of their surgical assignment (unmasked) after waking up from surgery and prior to discharge.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sacrocolpopexy

Minimally invasive supracervical hysterectomy with sacrocolpopexy (MI-SCH+SCP)

Group Type ACTIVE_COMPARATOR

Minimally invasive supracervical hysterectomy and sacrocolpopexy (MI-SCH+SCP)

Intervention Type PROCEDURE

Minimally invasive robotic or laparoscopic supracervical hysterectomy will be done, and the vaginal apex (including cervix) will be suspended utilizing sacrocolpopexy mesh to the anterior spinous ligament.

Uterosacral Ligament Suspension

Total vaginal hysterectomy with uterosacral ligament suspension (TVH+USLS)

Group Type ACTIVE_COMPARATOR

Vaginal hysterectomy with uterosacral ligament suspension (TVH+USLS)

Intervention Type PROCEDURE

The uterus will be removed vaginally and the vaginal apex will be suspended utilizing sutures in the uterosacral ligament.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Minimally invasive supracervical hysterectomy and sacrocolpopexy (MI-SCH+SCP)

Minimally invasive robotic or laparoscopic supracervical hysterectomy will be done, and the vaginal apex (including cervix) will be suspended utilizing sacrocolpopexy mesh to the anterior spinous ligament.

Intervention Type PROCEDURE

Vaginal hysterectomy with uterosacral ligament suspension (TVH+USLS)

The uterus will be removed vaginally and the vaginal apex will be suspended utilizing sutures in the uterosacral ligament.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Women ≥ 18 years of age and ≤ 80 years of age
2. Have diagnosis of symptomatic uterovaginal prolapse
3. Have elected to undergo surgical management of uterovaginal prolapse after consultation with their physician
4. Are eligible for both minimally invasive supracervical hysterectomy with sacrocolpopexy (MI-SCH+SCP) and total vaginal hysterectomy with uterosacral ligament suspension (TVH+USLS)

Exclusion Criteria

1. Patients who wish to undergo uterine sparing procedures
2. Body mass index BMI) \> 50
3. Previous hysterectomy or prior uterovaginal surgery
4. Have a diagnosis of neurogenic bladder, Parkinson's disease, multiple sclerosis, spinal cord injury, or cerebrovascular accident
5. Chronic indwelling urinary catheter
6. Urinary diversion of any type
7. Any condition or disorder that, in the opinion of the investigator, might prevent the subject from completing the study or interfere with the interpretation of the study results
8. Unable to speak, read, understand English
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Case Western Reserve University

OTHER

Sponsor Role collaborator

MetroHealth Medical Center

OTHER

Sponsor Role collaborator

The Cleveland Clinic

OTHER

Sponsor Role collaborator

Duke University

OTHER

Sponsor Role collaborator

University of Pittsburgh

OTHER

Sponsor Role collaborator

Mayo Clinic

OTHER

Sponsor Role collaborator

Northwestern Medicine

OTHER

Sponsor Role collaborator

University Hospitals Cleveland Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Adonis Hijaz, MD

Professor of Urology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Adonis Hijaz, MD

Role: PRINCIPAL_INVESTIGATOR

University Hospitals Cleveland Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mayo Clinic

Jacksonville, Florida, United States

Site Status RECRUITING

Northwestern Medicine

Chicago, Illinois, United States

Site Status RECRUITING

Duke University

Durham, North Carolina, United States

Site Status RECRUITING

University Hospitals Cleveland Medical Center

Cleveland, Ohio, United States

Site Status RECRUITING

MetroHealth Medical Center

Cleveland, Ohio, United States

Site Status RECRUITING

Cleveland Clinic

Cleveland, Ohio, United States

Site Status RECRUITING

University of Pittsburgh, UPMC Magee-Womens Hospital

Pittsburgh, Pennsylvania, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Grace Moss

Role: CONTACT

216-286-8005

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Study Coordinator

Role: primary

9049532979

Catherine Campusano

Role: primary

312-695-7194

Eilza Sorrell

Role: primary

919-401-1015

Grace Moss

Role: primary

216-286-8005

Stephanie Kanuch

Role: primary

216-280-2915

Sheila Woodruff

Role: primary

216-445-2494

Lindsey Baranski

Role: primary

412-641-7894

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

20210871

Identifier Type: -

Identifier Source: org_study_id